1
|
Vanhersecke L, Brunet M, Guégan JP, Rey C, Bougouin A, Cousin S, Moulec SL, Besse B, Loriot Y, Larroquette M, Soubeyran I, Toulmonde M, Roubaud G, Pernot S, Cabart M, Chomy F, Lefevre C, Bourcier K, Kind M, Giglioli I, Sautès-Fridman C, Velasco V, Courgeon F, Oflazoglu E, Savina A, Marabelle A, Soria JC, Bellera C, Sofeu C, Bessede A, Fridman WH, Loarer FL, Italiano A. Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression. Nat Cancer 2021; 2:794-802. [PMID: 35118423 PMCID: PMC8809887 DOI: 10.1038/s43018-021-00232-6] [Citation(s) in RCA: 167] [Impact Index Per Article: 55.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/05/2023]
Abstract
Only a minority of patients derive long-term clinical benefit from anti-PD1/PD-L1 monoclonal antibodies. The presence of tertiary lymphoid structures (TLS) has been associated with improved survival in several tumor types. Here, using a large-scale retrospective analysis of three independent cohorts of cancer patients treated with anti-PD1/PD-L1 antibodies, we showed that the presence of mature TLS was associated with improved objective response rate, progression-free survival, and overall survival independently of PD-L1 expression status and CD8+ T-cell density. These results pave the way for using TLS detection to select patients who are more likely to benefit from immune checkpoint blockade.
Collapse
Affiliation(s)
- Lucile Vanhersecke
- Department of Pathology, Institut Bergonié, Bordeaux, France
- Faculty of Medicine, University of Bordeaux, Bordeaux, France
| | - Maxime Brunet
- Faculty of Medicine, University of Bordeaux, Bordeaux, France
- Department of Medicine, Institut Bergonié, Bordeaux, France
| | | | | | - Antoine Bougouin
- Centre de Recherche des Cordeliers, INSERM, Sorbonne Université, USPC, Université de Paris, Paris, 75006 France
| | - Sophie Cousin
- Department of Medicine, Institut Bergonié, Bordeaux, France
| | | | - Benjamin Besse
- Gustave Roussy, Department of Medicine, Villejuif, France
| | - Yohann Loriot
- Gustave Roussy, Department of Medicine, Villejuif, France
| | - Mathieu Larroquette
- Faculty of Medicine, University of Bordeaux, Bordeaux, France
- Department of Medicine, Institut Bergonié, Bordeaux, France
| | | | - Maud Toulmonde
- Department of Medicine, Institut Bergonié, Bordeaux, France
| | | | - Simon Pernot
- Department of Medicine, Institut Bergonié, Bordeaux, France
| | | | - François Chomy
- Department of Medicine, Institut Bergonié, Bordeaux, France
| | | | - Kevin Bourcier
- Department of Medicine, Institut Bergonié, Bordeaux, France
| | - Michèle Kind
- Department of Radiology, Institut Bergonié, Bordeaux, France
| | - Ilenia Giglioli
- Centre de Recherche des Cordeliers, INSERM, Sorbonne Université, USPC, Université de Paris, Paris, 75006 France
| | - Catherine Sautès-Fridman
- Centre de Recherche des Cordeliers, INSERM, Sorbonne Université, USPC, Université de Paris, Paris, 75006 France
| | - Valérie Velasco
- Department of Pathology, Institut Bergonié, Bordeaux, France
| | | | | | | | | | | | - Carine Bellera
- Clinical Research and Clinical Epidemiology Unit (ISO 9001 Certified), Institut Bergonié, Comprehensive Cancer Centre, 229 Cours de l'Argonne, 33076 Bordeaux, France
| | - Casimir Sofeu
- Clinical Research and Clinical Epidemiology Unit (ISO 9001 Certified), Institut Bergonié, Comprehensive Cancer Centre, 229 Cours de l'Argonne, 33076 Bordeaux, France
| | | | - Wolf H Fridman
- Centre de Recherche des Cordeliers, INSERM, Sorbonne Université, USPC, Université de Paris, Paris, 75006 France
| | - François Le Loarer
- Department of Pathology, Institut Bergonié, Bordeaux, France
- Faculty of Medicine, University of Bordeaux, Bordeaux, France
| | - Antoine Italiano
- Faculty of Medicine, University of Bordeaux, Bordeaux, France
- Department of Medicine, Institut Bergonié, Bordeaux, France
- Gustave Roussy, Department of Medicine, Villejuif, France
| |
Collapse
|
2
|
Ben-Ami E, Perret R, Huang Y, Courgeon F, Gokhale PC, Laroche-Clary A, Eschle BK, Velasco V, Le Loarer F, Algeo MP, Purcell J, Demetri GD, Italiano A. LRRC15 Targeting in Soft-Tissue Sarcomas: Biological and Clinical Implications. Cancers (Basel) 2020; 12:E757. [PMID: 32210091 PMCID: PMC7140027 DOI: 10.3390/cancers12030757] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2020] [Revised: 03/12/2020] [Accepted: 03/17/2020] [Indexed: 01/09/2023] Open
Abstract
BACKGROUND LRRC15 is a member of the LRR (leucine-rich repeat) superfamily present on tumor-associated fibroblasts (CAFs) and stromal cells. The expression of LRRC15 is upregulated by the pro-inflammatory cytokine TGFβ. ABBV-085 is a monomethyl auristatin E (MMAE)-containing antibody-drug conjugate (ADC) designed to target LRRC15, and which has shown significant anti-tumor activity in several tumor models. This is the first focused examination of LRRC15 expression and ABBV-085 activity in soft-tissue sarcomas (STS). METHODS We analyzed the LRRC15 expression profile by immunohistochemistry in 711 STS cases, covering a broad spectrum of STS histologies and sub-classifications. In vivo experiments were carried out by using LRRC15-positive and LRRC15-negative patient-derived xenograft (PDX) models of STS. RESULTS In contrast to patterns observed in epithelial tumors, LRRC15 was expressed not only by stromal cells but also by cancer cells in multiple subsets of STS with significant variations noted between histological subtypes. Overexpression of LRRC15 is positively correlated with grade and independently associated with adverse outcome. ABBV-085 has robust preclinical efficacy against LRRC15 positive STS patient-derived xenograft (PDX) models. CONCLUSION We provide the first preclinical evidence that LRRC15 targeting with an antibody-drug conjugate is a promising strategy in LRRC15-positive STS. ABBV-085 is being evaluated in an ongoing clinical trial in STS and other malignancies.
Collapse
Affiliation(s)
- Eytan Ben-Ami
- Sarcoma Division, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; (E.B.-A.); (Y.H.); (P.C.G.); (B.K.E.); (G.D.D.)
| | - Raul Perret
- Department of Pathology, Institut Bergonié, 33000 Bordeaux, France; (R.P.); (V.V.); (F.L.L.)
| | - Ying Huang
- Sarcoma Division, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; (E.B.-A.); (Y.H.); (P.C.G.); (B.K.E.); (G.D.D.)
| | - Félicie Courgeon
- Sarcoma Unit, Institut Bergonié, 33000 Bordeaux, France; (F.C.); (A.L.-C.)
- INSERMU1218, 33000 Bordeaux, France
| | - Prafulla C. Gokhale
- Sarcoma Division, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; (E.B.-A.); (Y.H.); (P.C.G.); (B.K.E.); (G.D.D.)
| | - Audrey Laroche-Clary
- Sarcoma Unit, Institut Bergonié, 33000 Bordeaux, France; (F.C.); (A.L.-C.)
- INSERMU1218, 33000 Bordeaux, France
| | - Benjamin K. Eschle
- Sarcoma Division, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; (E.B.-A.); (Y.H.); (P.C.G.); (B.K.E.); (G.D.D.)
| | - Valérie Velasco
- Department of Pathology, Institut Bergonié, 33000 Bordeaux, France; (R.P.); (V.V.); (F.L.L.)
| | - François Le Loarer
- Department of Pathology, Institut Bergonié, 33000 Bordeaux, France; (R.P.); (V.V.); (F.L.L.)
| | | | - James Purcell
- AbbVie Biotherapeutics, Redwood City, CA 94063, USA;
| | - George D. Demetri
- Sarcoma Division, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; (E.B.-A.); (Y.H.); (P.C.G.); (B.K.E.); (G.D.D.)
- Ludwig Center at Harvard, Harvard Medical School, Boston, MA 02215, USA
| | - Antoine Italiano
- Sarcoma Unit, Institut Bergonié, 33000 Bordeaux, France; (F.C.); (A.L.-C.)
- INSERMU1218, 33000 Bordeaux, France
- University of Bordeaux, 33400 Talence, France;
| |
Collapse
|